Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teva Pharma (NYSE:TEVA), Regeneron (NASDAQ:REGN) and Resmed Inc (NYSE:RMD).
Teva Pharma (TEVA)
In a report released yesterday, Douglas Tsao from Barclays maintained a Hold rating on Teva Pharma, with a price target of $23. The company’s shares closed yesterday at $21.61.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of 1.3% and a 50.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Protagonist Therapeutics, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Teva Pharma is a Hold with an average price target of $22.91, a 6.0% upside from current levels. In a report issued on July 18, Cantor Fitzgerald also assigned a Hold rating to the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Regeneron (REGN)
Barclays analyst Geoff Meacham maintained a Sell rating on Regeneron yesterday and set a price target of $305. The company’s shares closed yesterday at $397.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.5% and a 55.3% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Achillion Pharmaceuticals, and United Therapeutics.
Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $380.83.
Resmed Inc (RMD)
Northland Securities analyst Suraj Kalia maintained a Hold rating on Resmed Inc today and set a price target of $80. The company’s shares closed yesterday at $108.61, close to its 52-week high of $109.97.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 15.5% and a 61.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Resmed Inc has an analyst consensus of Hold, with a price target consensus of $91.50, which is a -15.8% downside from current levels. In a report released yesterday, BMO Capital also reiterated a Hold rating on the stock with a $103 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
